Form 4: Matinas BioPharma Holdings Insider Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Adam K Stern, a 10% owner of Matinas BioPharma Holdings, Inc., reported multiple transactions in common stock on October 16, 2025.

Summary

  • In-the-money derivative exercise: acquired 92,100 Common Stock, par value $0.0001 per share at $0.64 ($59,368) on October 31, 2025; holds 113,450 after (Indirect).
  • In-the-money derivative exercise: acquired 344,710 Common Stock, par value $0.0001 per share at $0.35 ($120,648) on July 10, 2026; holds 416,900 after (Indirect).
  • In-the-money derivative exercise: acquired 630,335 Common Stock, par value $0.0001 per share at $0.35 ($220,617) on July 10, 2026; holds 743,785 after (Indirect).
  • Other acquisition/disposition: acquired 800,000 Warrants to Purchase Common Stock at $0.64 ($515,680) on October 16, 2025; holds 800,000 after (Indirect).
  • Other acquisition/disposition: acquired 265 Series C Convertible Preferred Stock at $0.59 ($155) on October 16, 2025; holds 265 after (Indirect).
  • In-the-money derivative exercise: disposed of 92,100 Warrants to Purchase Common Stock at $0.64 ($59,368) on October 31, 2025; holds 630,335 after (Indirect).
  • In-the-money derivative exercise: disposed of 630,335 Warrants to Purchase Common Stock at $0.35 ($220,617) on July 10, 2026 (Indirect).
  • Grant/award: acquired 630,335 Warrants to Purchase Common Stock at $0.35 ($220,617) on July 10, 2026; holds 630,335 after (Indirect).
  • In-the-money derivative exercise: disposed of 344,710 Warrants to Purchase Common Stock at $0.35 ($120,648) on July 10, 2026 (Indirect).
  • Grant/award: acquired 344,710 Warrants to Purchase Common Stock at $0.35 ($120,648) on July 10, 2026; holds 344,710 after (Indirect).
  • Other acquisition/disposition: acquired 141,462 Warrants to Purchase Common Stock at $0.35 ($49,512) on July 10, 2026; holds 141,462 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Adam K Stern — 10% owner

DateTransactionSecuritySharesPriceValueHeld After
2025-10-31In-the-money derivative exerciseCommon Stock, par value $0.0001 per share92,100$1$59.4K113,450
2026-07-10In-the-money derivative exerciseCommon Stock, par value $0.0001 per share344,710$0$120.6K416,900
2026-07-10In-the-money derivative exerciseCommon Stock, par value $0.0001 per share630,335$0$220.6K743,785
2025-10-16Other acquisition/dispositionWarrants to Purchase Common Stock800,000$1$515.7K800,000
2025-10-16Other acquisition/dispositionSeries C Convertible Preferred Stock265$1$155265
2025-10-31In-the-money derivative exerciseWarrants to Purchase Common Stock92,100$1$59.4K630,335
2026-07-10In-the-money derivative exerciseWarrants to Purchase Common Stock630,335$0$220.6K0
2026-07-10Grant/awardWarrants to Purchase Common Stock630,335$0$220.6K630,335
2026-07-10In-the-money derivative exerciseWarrants to Purchase Common Stock344,710$0$120.6K0
2026-07-10Grant/awardWarrants to Purchase Common Stock344,710$0$120.6K344,710
2026-07-10Other acquisition/dispositionWarrants to Purchase Common Stock141,462$0$49.5K141,462

Key Dates

DateDescription
2025-10-31In-the-money derivative exercise (92,100 shares)
2026-07-10In-the-money derivative exercise (344,710 shares)
2026-07-10In-the-money derivative exercise (630,335 shares)
2025-10-16Other acquisition/disposition (800,000 shares)
2025-10-16Other acquisition/disposition (265 shares)
2025-10-31In-the-money derivative exercise (92,100 shares)
2026-07-10In-the-money derivative exercise (630,335 shares)
2026-07-10Grant/award (630,335 shares)
2026-07-10In-the-money derivative exercise (344,710 shares)
2026-07-10Grant/award (344,710 shares)
2026-07-10Other acquisition/disposition (141,462 shares)

Keywords

insider transaction, Form 4, MTNB, Matinas BioPharma Holdings, Inc., neutral, Adam K Stern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.